Drug intelligence / Profile preview

PTX-108

Development stage: Unknown
Lead developer: Providence Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PTX-108 is an mRNA-based cancer vaccine developed by Providence Therapeutics for the treatment of pediatric brain cancer. The vaccine utilizes messenger RNA to encode specific pediatric brain tumor antigens, aiming to stimulate the patient's immune system to recognize and mount a targeted response against malignant brain tumor cells. By delivering the genetic instructions for these antigens directly to the patient's cells, PTX-108 facilitates the endogenous production of tumor-specific proteins that are then presented to the immune system. It is currently in Phase 1 clinical development.

Beyond the preview

Go deeper on PTX-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-108.

Explore the full profile